INDEMNIFICATION AGREEMENTIndemnification Agreement • December 30th, 2020 • Vincera Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ___________, 20__ between Vincera Pharma, Inc., a Delaware corporation (the “Company”), and _____________ (“Indemnitee”).
AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENTRegistration and Stockholder Rights Agreement • December 30th, 2020 • Vincera Pharma, Inc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this “Agreement”) is entered into as of the 23rd day of December 2020, by and among LifeSci Acquisition Corp., a Delaware corporation (the “Company”), and the persons and entities listed on Schedule A attached hereto (the “Stockholders”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • December 30th, 2020 • Vincera Pharma, Inc. • Pharmaceutical preparations • California
This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), dated as of December 23, 2020, is by and between Vincera Pharma, Inc., a Delaware corporation (the “Company”), and Raquel Izumi PhD (“Executive”).
VINCERA PHARMA, INC. 2020 STOCK INCENTIVE PLAN (Adopted by the Board of Directors on December 16, 2020) (Approved by the Stockholders on December 22, 2020) (Effective on December 23, 2020)2020 Stock Incentive Plan • December 30th, 2020 • Vincera Pharma, Inc. • Pharmaceutical preparations • Delaware
MERGER AGREEMENT dated September 25, 2020 by and among LifeSci Acquisition Corp., a Delaware corporation as the Purchaser, LifeSci Acquisition Merger Sub, Inc., Delaware corporation, as Merger Sub, Vincera Pharma, Inc., a Delaware corporation, as the...Merger Agreement • December 30th, 2020 • Vincera Pharma, Inc. • Pharmaceutical preparations • Delaware
This MERGER AGREEMENT (the “Agreement”), dated as of September 25, 2020, by and among LifeSci Acquisition Corp., a Delaware corporation (the “Purchaser”), LifeSci Acquisition Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Purchaser (“Merger Sub”), Vincera Pharma, Inc., a Delaware corporation (the “Company”), and Raquel Izumi, an individual (the “Stockholders’ Representative”), as the representative of the stockholders of the Company (each, a “Stockholder” and collectively the “Stockholders”).
STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - GROSSVincera Pharma, Inc. • December 30th, 2020 • Pharmaceutical preparations
VOTING AND SUPPORT AGREEMENTVoting and Support Agreement • December 30th, 2020 • Vincera Pharma, Inc. • Pharmaceutical preparations • Delaware
THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made as of December 23, 2020, by and among LifeSci Acquisition Corp., a Delaware corporation (the “Company”), the persons and entities listed on Schedule A attached hereto (the “Founder Stockholders”), and the persons and entities listed on Schedule B attached hereto (the “Investor Stockholders,” and together with the Founder Stockholders, the “Voting Stockholders”). The Voting Stockholders and the Company are each a “party” and are collectively the “parties.”
RESALE LOCK-UP AGREEMENTResale Lock-Up Agreement • December 30th, 2020 • Vincera Pharma, Inc. • Pharmaceutical preparations • Delaware
This Resale Lock-Up Agreement (this “Agreement”) is dated as of December 23, 2020, by and between the stockholder set forth on the signature page to this Agreement (the “Holder”) and LifeSci Acquisition Corp., a Delaware corporation (the “Purchaser”). Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Merger Agreement (as defined below).
LICENSE AGREEMENTLicense Agreement • December 30th, 2020 • Vincera Pharma, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”), executed on Oct. 07, 2020 (the “Execution Date”), is entered into by and between Bayer Aktiengesellschaft, - having a place of business at Müllerstraße 178, 13353 Berlin, Germany -, Bayer Intellectual Property GmbH, having a place of business at Alfred-Nobel-Straße 10, 40789 Monheim am Rhein, Germany (all such Bayer entities being jointly and severally referred to as “Bayer”); and Vincera Pharma, Inc.(“Vincera”), having a place of business at 4500 Great America Parkway, Suite 100 #29, Santa Clara, California 95054, United States of America. Bayer and Vincera are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
